After Tandem and Dexcom reported stronger than anticipated second quarter growth everyone just assumed that Insulet would follow suit. Shares of the company were up strong today over 4%. Well so much for assumptions as Insulet has revised their full year guidance downward. Per the earnings press release;
“For the year ending December 31, 2018, the Company is revising its revenue guidance to a range of $547 to $562 million, representing growth of approximately 18% to 21% (previously $565 to $580 million), compared to 2017 revenue of $463.8 million. The Company is revising its expectations for its International Omnipod . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.